AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2017
Aug 3, 2017
31580_dirs_2017-08-03_1ed7998b-d8fe-4ec7-b615-48cfcf321f83.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2017-08-01
Reporting Person: Schenkein David P (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-01 | Common stock | M | 3000 | $0.3025 | Acquired | 3000 | Direct |
| 2017-08-01 | Common stock | S | 3000 | $55.12 | Disposed | 0 | Direct |
| 2017-08-02 | Common stock | M | 24000 | $0.3025 | Acquired | 24000 | Direct |
| 2017-08-02 | Common stock | S | 24000 | $60.55 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-01 | Stock option (right to buy) | $0.3025 | M | 3000 | Disposed | 2019-08-12 | Common stock (3000) | Direct |
| 2017-08-02 | Stock option (right to buy) | $0.3025 | M | 24000 | Disposed | 2019-08-12 | Common stock (24000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common stock | 272272 | Indirect |
| Common stock | 79082 | Indirect |
Footnotes
F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $54.61 to $55.90. The
reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer,
to provide full information regarding the number of shares sold at each separate price.
F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $61.71. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.
F6: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.
F7: This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.